^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + KSQ-4279 (USP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors
Published date:
10/12/2022
Excerpt:
...when we tested KSQ-4279 in combination with Olaparib in PARPi-resistant, BRCA mutant, triple-negative breast cancer (TNBC)-derived PDX models, we observed significantly greater and more durable anti-tumor activity, including regressions, with the combination therapy compared to single agents.